Login to Your Account

Affymax Partners Anemia Drug In Japan For $102M

By Karen Pihl-Carey

Tuesday, February 14, 2006
Less than a month after Affymax Inc. started the fourth Phase II trial of its lead product, Hematide, to treat anemia, the company signed a partnership deal in Japan worth up to $102 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription